Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : REX-8756
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,325.0 million
Deal Type : Collaboration
Recludix Names Oral STAT6 Inhibitor Candidate for Inflammatory Diseases with Sanofi
Details : The collaboration aims to advance preclinical studies, REX-8756, an oral, selective and reversible small molecule inhibitor of STAT6. It is being evaluated for asthma, COPD etc.
Product Name : REX-8756
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 02, 2025
Lead Product(s) : REX-8756
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,325.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,325.0 million
Deal Type : Collaboration
Details : Under the collaboration, Sanofi will have global rights to small molecule STAT6 inhibitors and Recludix will advance STAT6 inhibitors for patients with immunological and inflammatory diseases, from preclinical R&D until the start of Phase 2 clinical tria...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,325.0 million
Deal Type : Collaboration